Clinical Trial Update: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [Phase 3]

View source ↗

Summary

Phase 3 trial comparing nivolumab plus ipilimumab vs standard of care in first-line recurrent/metastatic squamous cell carcinoma of the head and neck; study com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Head and Neck Cancer | Phase 3 | Status: COMPLETED | Results posted: 2022-05-03